Breakdown of membrane choline-phospholipids induced by endogenous and exogenous muscarinic agonist is potentiated by VIP in rat submandibular gland.
The outflow of tritium from rat submandibular gland fragments, pre-labelled with [3H]choline, following electrical or pharmacological stimulation was studied. Electrical stimulation of the tissue increased the outflow of tritium in a frequency dependent manner. Atropine treatment decreased the electrically-induced release, indicating that the outflow did not reflect acetylcholine from nerve endings, but was largely brought about by postsynaptic receptors. In agreement with this hypothesis, treatment with noradrenaline or carbachol induced a dose dependent increase in tritium outflow from the gland fragments which could be blocked by prazosin or atropine, respectively. Moreover, analysis of the tissue-associated tritium revealed an incorporation primarily in the lipid fraction of the tissue (almost 80%), of which about 90% was in phosphatidylcholine, indicating that this was the source of the tritium outflow. Pre-incubation with vasoactive intestinal polypeptide (VIP), which coexists with acetylcholine in the parasympathetic neurons innervating the submandibular gland, increased the carbachol-induced tritium overflow significantly. The effect of VIP could be imitated by the adenylyl cyclase stimulator forskolin, which increased the carbachol-stimulated tritium efflux in a dose dependent manner. Taken together, our results suggests that muscarinic- and alpha 1-receptor agonists may activate a phospholipase coupled to phosphatidylcholine hydrolysis in the rat submandibular gland. Endogenous acetylcholine released from parasympathetic nerve endings appear to activate this mechanism. Furthermore, VIP treatment, and the concomitant cAMP-accumulation, potentiates the acetylcholine induced phosphatidylcholine hydrolysis, demonstrating a new type of interaction between the classical transmitter acetylcholine and the co-stored neuropeptide VIP.
Dunér-Engström
M
M
Department of Pharmacology, Karolinska Institute, Sweden.
Fredholm
B B
BB
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D004357:Drug Synergism; D004558:Electric Stimulation; D066298:In Vitro Techniques; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010277:Parasympathomimetics / Q000494:pharmacology*; D010477:Perfusion; D010713:Phosphatidylcholines / Q000378:metabolism*; D010740:Phospholipases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D013268:Stimulation, Chemical; D013363:Submandibular Gland / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D010277:Parasympathomimetics; D010713:Phosphatidylcholines; D018340:Receptors, Adrenergic, alpha-1; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D001285:Atropine; D002217:Carbachol; D010740:Phospholipases